ASH Lymphoma eBook
Focus on ASH Lymphoma 2023v2.indd
Read MoreDec 19, 2022
Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score had...
Read MoreDec 16, 2022
Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of...
Read MoreDec 15, 2022
Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...
Read MoreDec 15, 2022
Consolidation high-dose chemotherapy followed by autologous stem cell transplantation (HCT/ASCT)...
Read MoreDec 15, 2022
In patients with previously untreated mantle cell lymphoma (MCL), autologous stem cell...
Read MoreDec 6, 2022
Friday, December 9th 7:00 a.m.– 6:00 p.m. Registration open (for in-person participants) 7:00 a.m. – 10:00 a.m. Friday Satellite Symposia 9:00 a.m. – 12:00 Training Program Directors’ Workshop 11:00 a.m. – 2:00 p.m. Friday...
Read MoreDec 6, 2022
Key Protocols: Vaccination will be required for all in-person meeting attendees. ASH is offering complimentary* medical evacuation and quarantine support coverage. Proof of a negative COVID-19 test is not required for in-person...
Read MoreDec 6, 2022
The ASH Foundation Run & Walk will start and finish on Convention Center Boulevard and Julia Street, head toward the Riverwalk near the Audubon Aquarium of the Americas, and go through Woldenberg Park. Schedule: 7:00 a.m....
Read MoreDec 6, 2022
FSS are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company. Morning Topics: A Thread To Pull: Unraveling The...
Read MoreNov 30, 2022
African American (AA) patients with diffuse large b-cell lymphoma (DLBCL) experience differences...
Read MoreNov 29, 2022
The most prevalent B-cell non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). Various...
Read MoreNov 28, 2022
A number of CD19-targeted medicines, such as chimeric antigen receptor T-cell therapy (CAR-T),...
Read MoreNov 28, 2022
For tailored therapy selection and result optimization in diffuse large B-cell lymphoma (DLBCL),...
Read More